Mosquito-borne Diseases Drug Development Pipeline Review, 2018
Summary
West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.
Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.
Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.
Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.
Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.
This report “Mosquito-borne Diseases Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 Mosquito-borne Diseases Report Coverage
- 2.2 West Nile Virus Infections - Overview
- 2.3 Japanese Encephalitis - Overview
- 2.4 Yellow Fever - Overview
- 2.5 Malaria - Overview
- 3 Therapeutics Development
- 3.1 West Nile Virus Infections
- 3.2 Japanese Encephalitis
- 3.3 Yellow Fever
- 3.4 Malaria
- 4 Therapeutics Assessment
- 4.1 West Nile Virus Infections
- 4.2 Japanese Encephalitis
- 4.3 Yellow Fever
- 4.4 Malaria
- 5 Companies Involved in Therapeutics Development
- 5.1 West Nile Virus Infections
- 5.2 Japanese Encephalitis
- 5.3 Yellow Fever
- 5.4 Malaria
- 6 Dormant Projects
- 6.1 West Nile Virus Infections
- 6.2 Japanese Encephalitis
- 6.3 Yellow Fever
- 6.4 Malaria
- 7 Discontinued Products
- 7.1 Japanese Encephalitis
- 7.2 Malaria
- 8 Product Development Milestones
- 8.1 West Nile Virus Infections
- 8.2 Yellow Fever
- 8.3 Malaria
- 9 Appendix
- 9.1 Methodology
- 9.2 Coverage
- 9.3 Secondary Research
- 9.4 Primary Research
- 9.5 Expert Panel Validation
- 9.6 Contact Us
- 9.7 Disclaimer
- 1.1 List of Tables
- Table 1: Number of Products under Development for West Nile Virus Infections
- Table 2: Number of Products under Development by Companies, West Nile Virus Infections
- Table 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections
- Table 4: Products under Development by Companies, West Nile Virus Infections
- Table 5: Products under Development by Universities/Institutes, West Nile Virus Infections
- Table 6: Number of Products under Development for Japanese Encephalitis
- Table 7: Number of Products under Development by Companies, Japanese Encephalitis
- Table 8: Number of Products under Development by Universities/Institutes, Japanese Encephalitis
- Table 9: Products under Development by Companies, Japanese Encephalitis
- Table 10: Products under Development by Universities/Institutes, Japanese Encephalitis
- Table 11: Number of Products under Development for Yellow Fever
- Table 12: Number of Products under Development by Companies, Yellow Fever
- Table 13: Number of Products under Development by Universities/Institutes, Yellow Fever
- Table 14: Products under Development by Companies, Yellow Fever
- Table 15: Products under Development by Universities/Institutes, Yellow Fever
- Table 16: Number of Products under Development for Malaria
- Table 17: Number of Products under Development by Companies, Malaria
- Table 18: Number of Products under Development by Universities/Institutes, Malaria
- Table 19: Products under Development by Companies, Malaria
- Table 20: Products under Development by Universities/Institutes, Malaria
- Table 21: Number of Products by Stage and Target, West Nile Virus Infections
- Table 22: Number of Products by Stage and Mechanism of Action, West Nile Virus Infections
- Table 23: Number of Products by Stage and Route of Administration, West Nile Virus Infections
- Table 24: Number of Products by Stage and Molecule Type, West Nile Virus Infections
- Table 25: Number of Products by Stage and Target, Japanese Encephalitis
- Table 26: Number of Products by Stage and Mechanism of Action, Japanese Encephalitis
- Table 27: Number of Products by Stage and Route of Administration, Japanese Encephalitis
- Table 28: Number of Products by Stage and Molecule Type, Japanese Encephalitis
- Table 29: Number of Products by Stage and Target, Yellow Fever
- Table 30: Number of Products by Stage and Mechanism of Action, Yellow Fever
- Table 31: Number of Products by Stage and Route of Administration, Yellow Fever
- Table 32: Number of Products by Stage and Molecule Type, Yellow Fever
- Table 33: Number of Products by Stage and Target, Malaria
- Table 34: Number of Products by Stage and Mechanism of Action, Malaria
- Table 35: Number of Products by Stage and Route of Administration, Malaria
- Table 36: Number of Products by Stage and Molecule Type, Malaria
- Table 37: West Nile Virus Infections - Pipeline by CEL-SCI Corp
- Table 38: West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC
- Table 39: West Nile Virus Infections - Pipeline by Hawaii Biotech Inc
- Table 40: West Nile Virus Infections - Pipeline by Hemispherx Biopharma Inc
- Table 41: West Nile Virus Infections - Pipeline by Kineta Inc
- Table 42: West Nile Virus Infections - Pipeline by Ology Bioservices Inc
- Table 43: West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc
- Table 44: Japanese Encephalitis - Pipeline by Abivax SA
- Table 45: Japanese Encephalitis - Pipeline by Adimmune Corp
- Table 46: Japanese Encephalitis - Pipeline by Cadila Healthcare Ltd
- Table 47: Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC
- Table 48: Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd
- Table 49: Japanese Encephalitis - Pipeline by Kineta Inc
- Table 50: Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc
- Table 51: Japanese Encephalitis - Pipeline by Panacea Biotec Ltd
- Table 52: Japanese Encephalitis - Pipeline by Sinovac Biotech Ltd
- Table 53: Yellow Fever - Pipeline by Bavarian Nordic A/S
- Table 54: Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc
- Table 55: Yellow Fever - Pipeline by Emergex Vaccines Ltd
- Table 56: Yellow Fever - Pipeline by Ennaid Therapeutics LLC
- Table 57: Yellow Fever - Pipeline by iBio Inc
- Table 58: Yellow Fever - Pipeline by Ology Bioservices Inc
- Table 59: Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd
- Table 60: Yellow Fever - Pipeline by Valneva SE
- Table 61: Malaria - Pipeline by 4SC AG
- Table 62: Malaria - Pipeline by AbbVie Inc
- Table 63: Malaria - Pipeline by Agilvax Inc
- Table 64: Malaria - Pipeline by Akshaya Bio Inc
- Table 65: Malaria - Pipeline by AlfaSigma SpA
- Table 66: Malaria - Pipeline by Allergy Therapeutics Plc
- Table 67: Malaria - Pipeline by Altimmune Inc
- Table 68: Malaria - Pipeline by Artificial Cell Technologies Inc
- Table 69: Malaria - Pipeline by AstraZeneca Plc
- Table 70: Malaria - Pipeline by Bharat Biotech Ltd
- 1.2 List of Figures
- Figure 1: Number of Products under Development for West Nile Virus Infections
- Figure 2: Number of Products under Development by Companies, West Nile Virus Infections
- Figure 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections
- Figure 4: Number of Products under Development for Japanese Encephalitis
- Figure 5: Number of Products under Development by Companies, Japanese Encephalitis
- Figure 6: Number of Products under Development by Universities/Institutes, Japanese Encephalitis
- Figure 7: Number of Products under Development for Yellow Fever
- Figure 8: Number of Products under Development by Companies, Yellow Fever
- Figure 9: Number of Products under Development by Universities/Institutes, Yellow Fever
- Figure 10: Number of Products under Development for Malaria
- Figure 11: Number of Products under Development by Companies, Malaria
- Figure 12: Number of Products under Development by Universities/Institutes, Malaria
- Figure 13: Number of Products by Targets, West Nile Virus Infections
- Figure 14: Number of Products by Stage and Targets, West Nile Virus Infections
- Figure 15: Number of Products by Mechanism of Actions, West Nile Virus Infections
- Figure 16: Number of Products by Stage and Mechanism of Actions, West Nile Virus Infections
- Figure 17: Number of Products by Routes of Administration, West Nile Virus Infections
- Figure 18: Number of Products by Stage and Routes of Administration, West Nile Virus Infections
- Figure 19: Number of Products by Molecule Types, West Nile Virus Infections
- Figure 20: Number of Products by Stage and Molecule Types, West Nile Virus Infections
- Figure 21: Number of Products by Routes of Administration, Japanese Encephalitis
- Figure 22: Number of Products by Stage and Routes of Administration, Japanese Encephalitis
- Figure 23: Number of Products by Molecule Types, Japanese Encephalitis
- Figure 24: Number of Products by Stage and Molecule Types, Japanese Encephalitis
- Figure 25: Number of Products by Targets, Yellow Fever
- Figure 26: Number of Products by Stage and Targets, Yellow Fever
- Figure 27: Number of Products by Mechanism of Actions, Yellow Fever
- Figure 28: Number of Products by Stage and Mechanism of Actions, Yellow Fever
- Figure 29: Number of Products by Routes of Administration, Yellow Fever
- Figure 30: Number of Products by Stage and Routes of Administration, Yellow Fever
- Figure 31: Number of Products by Molecule Types, Yellow Fever
- Figure 32: Number of Products by Stage and Molecule Types, Yellow Fever
- Figure 33: Number of Products by Targets, Malaria
- Figure 34: Number of Products by Stage and Targets, Malaria
- Figure 35: Number of Products by Top 10 Mechanism of Actions, Malaria
- Figure 36: Number of Products by Stage and Mechanism of Actions, Malaria
- Figure 37: Number of Products by Routes of Administration, Malaria
- Figure 38: Number of Products by Stage and Routes of Administration, Malaria
- Figure 39: Number of Products by Top 10 Molecule Types, Malaria
- Figure 40: Number of Products by Stage and Top 10 Molecule Types, Malaria